Devyser Diagnostics AB has finalized the acquisition of CyberGene AB from Level Bio AB. The strategic rationale for this transaction centers on a "portfolio-optimization" play, merging the target's established diagnostic kits in aneuploidy and infertility with the group's global commercial infrastructure and direct sales force. This fusion effectively creates a specialized powerhouse in the reproductive health market, providing the group with the necessary hardware to deepen its customer offering in clinical genetics laboratories. This operation allows Devyser Diagnostics to execute a definitive structural transformation of the target's existing market footprint. By absorbing an asset with a high level of customer acceptance but limited global reach, the organization can now leverage its industrialized R&D and sales machine to drive international scaling. The maneuver optimizes the group's financial profile, with the integration expected to yield immediate improvements in gross profit and consolidated EBIT margins. Ultimately, the partnership solidifies the group’s standing as a primary enabler of high-precision molecular diagnostics, while ensuring the organization remains an agile leader in the rapid evolution of genomic testing standards.

The transaction values CYBERGENE at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.